Commentary · 8 Jun 2026
Conference abstractPublished 11 Jun 2018
Neuropathophysiology cross-talk between Alzheimer′s and Parkinson′s disease
National Neuroscience Institute, Singapore The Experimental Therapeutics Centre (ETC)-A*STAR, Singapore Genome Institute of Singapore (GIS)-A*STAR, Singapore National University of Singapore, ingapore 5DUKE-NUS Medical School, Singapore
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common genetic cause of familial and sporadic ParkinsonâÂ?Â?s disease (PD). Amyloid precursor protein (APP) is an important molecule in AlzheimerâÂ?Â?s disease (AD). Although recent research revealed that there might be common pathophysiological and genetic links between these two diseases, little is known about the potential biological interplay between LRRK2 and APP. Materials & Methods: Here, we used LRRK2 G2019S mouse models and induced pluripotent stem cell (iPSC)âÂ?Â?derived neurons from PD patients to investigate the potential pathophysiological interplay between LRRK2 and APP in PD. Results: We demonstrate here that LRRK2 interacts with APP and LC/MS/MS analysis revealed LRRK2 phosphorylates APP at threonine-668 (T668). This in turn stimulates the production of the APP intracellular domain (AICD) and enhances AICD nuclear translocation, which is associated with the dopaminergic neuron loss in aging LRRK2 G2019S mutant mice. Importantly, we found that the expression of AICD exacerbates LRRK2 G2019S-induced neurotoxicity, whereas phosphomutant AICD (T668A) has no effect on LRRK2 G2019S-induced neuronal loss in vitro and in LRRK2 G2019S mutant mice. Moreover, dopaminergic neurons generated from LRRK2 G2019S patient-derived induced pluripotent stem cells exhibit significantly elevated phospho-APP T668 levels relative to their counterparts derived from healthy individuals. The level of T668- phosphorylated APP is also significantly increased in LRRK2 G2019S post-mortem human brain tissues. Treatment with LRRK2 inhibitors reduces phosphorylation at T668 in LRRK2 G2019S patientâÂ?Â?s dopaminergic neurons and in LRRK2 G2019S mutant mice. Discussion: APP and LRRK2 are physically and functionally linked, suggesting a shared pathway between the two most common neurodegenerative diseases that may help explain their overlapping pathology, especially in advanced stages of the respective disease. Conclusions: APP is a substrate of LRRK2, and its phosphorylation promotes AICD function and neurotoxicity in PD.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Alzheimers Disease & Parkinsonism.
Perspective · 8 Jun 2026
Oxidative Stress and Its Role in Neuronal Degeneration: Mechanisms and Implications
Commentary · 8 Jun 2026
Understanding the Pathophysiology of Prion-Induced Dementia
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Alzheimers Disease & Parkinsonism
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Li Zeng”
- BylineArticles whose byline prints “Zhongcan Chen”
- BylineArticles whose byline prints “Wei Zhang”
- BylineArticles whose byline prints “Ling Ling Chua”
- BylineArticles whose byline prints “Chou Chai”
- BylineArticles whose byline prints “Rong Li”
- BylineArticles whose byline prints “Lin Lin”
- BylineArticles whose byline prints “Zhen Cao”